Design, synthesis and antitumor activity evaluation of novel IMPDH II and HDAC1 dual inhibitor.

IF 4.1 4区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

RSC medicinal chemistry Pub Date : 2025-05-21 DOI:10.1039/d5md00007f

Fang-Bo Deng, Hong-Wei Jia, De-Xiang Hu, Zhen-Li Li, Xiao-Meng Xiu, Xue-Qi Zhao, Yang Liu, Hua-Li Yang, Maosheng Cheng

{"title":"Design, synthesis and antitumor activity evaluation of novel IMPDH II and HDAC1 dual inhibitor.","authors":"Fang-Bo Deng, Hong-Wei Jia, De-Xiang Hu, Zhen-Li Li, Xiao-Meng Xiu, Xue-Qi Zhao, Yang Liu, Hua-Li Yang, Maosheng Cheng","doi":"10.1039/d5md00007f","DOIUrl":null,"url":null,"abstract":"The development of multi-target inhibitors has garnered considerable attention in the field of cancer therapy. We have designed and synthesized a total of 80 derivatives, categorized into A, B, and C series. Among these compounds, C12 (hIMPDH II, IC50 = 84.69 ± 0.83 nM; HDAC1, IC50 = 81.75 ± 0.82 nM) and C18 (hIMPDH II, IC50 = 820.50 ± 1.41 nM; HDAC1, IC50 = 131.90 ± 1.02 nM) exhibited promising inhibitory activity against hIMPDH II and HDAC1. Compared to the IMPDH-positive compound MPA (IC50 = 403.23 ± 2.92 nM) and the HDAC-positive compound SAHA (IC50 = 1165.72 ± 1.22 nM), compound C12 (IC50 value of 305.31 ± 0.67 nM) demonstrated superior anti-proliferative activity against K-562 cells in vitro. Compound C12 exhibited good liver microsomal stability with a moderate half-life (T 1/2). Furthermore, compound C12 exhibited acceptable in vivo pharmacokinetics of properties. In conclusion, compound C12 represents a potential new dual inhibitor targeting both hIMPDH II and HDAC1.","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094184/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RSC medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1039/d5md00007f","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The development of multi-target inhibitors has garnered considerable attention in the field of cancer therapy. We have designed and synthesized a total of 80 derivatives, categorized into A, B, and C series. Among these compounds, C12 (hIMPDH II, IC₅₀ = 84.69 ± 0.83 nM; HDAC1, IC₅₀ = 81.75 ± 0.82 nM) and C18 (hIMPDH II, IC₅₀ = 820.50 ± 1.41 nM; HDAC1, IC₅₀ = 131.90 ± 1.02 nM) exhibited promising inhibitory activity against hIMPDH II and HDAC1. Compared to the IMPDH-positive compound MPA (IC₅₀ = 403.23 ± 2.92 nM) and the HDAC-positive compound SAHA (IC₅₀ = 1165.72 ± 1.22 nM), compound C12 (IC₅₀ value of 305.31 ± 0.67 nM) demonstrated superior anti-proliferative activity against K-562 cells in vitro. Compound C12 exhibited good liver microsomal stability with a moderate half-life (T _1/2). Furthermore, compound C12 exhibited acceptable in vivo pharmacokinetics of properties. In conclusion, compound C12 represents a potential new dual inhibitor targeting both hIMPDH II and HDAC1.

查看原文本刊更多论文

新型IMPDH II和HDAC1双抑制剂的设计、合成及抗肿瘤活性评价。

多靶点抑制剂的开发在癌症治疗领域引起了相当大的关注。我们共设计合成了80种衍生物，分为a、B、C系列。其中，C12 (hIMPDH II) IC50 = 84.69±0.83 nM；HDAC1, IC50 = 81.75±0.82 nM)和C18 (hIMPDH II, IC50 = 820.50±1.41 nM；HDAC1 （IC50 = 131.90±1.02 nM）对hIMPDH II和HDAC1具有良好的抑制活性。与impdh阳性化合物MPA （IC50 = 403.23±2.92 nM）和hdac阳性化合物SAHA （IC50 = 1165.72±1.22 nM）相比，化合物C12 （IC50值为305.31±0.67 nM）对K-562细胞具有更强的体外抗增殖活性。化合物C12表现出良好的肝微粒体稳定性，半衰期中等（t1 /2）。此外，化合物C12表现出可接受的体内药代动力学性质。综上所述，化合物C12是一种潜在的针对hIMPDH II和HDAC1的新型双重抑制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

RSC medicinal chemistry Multiple-

CiteScore

5.80

自引率

2.40%

发文量

129